Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human DLL3 Stable Cell Line

    [CAT#: S01YF-1023-PY266]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Product Information

    Target Family
    Other Targets
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;SBC-5
    Target Classification
    Other Targets Drug Discovery Assays and Products
    Target Research Area
    Metabolic Research
    Related Diseases
    Spondylocostal Dysostosis 1, Autosomal Recessive; Spondylocostal Dysostosis, Autosomal Recessive
    Gene ID
    Human:10683
    UniProt ID
    Human:Q9NYJ7

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    DLL3, or delta-like ligand 3, is a protein that has been studied in various contexts. In a study on mice, it was found that Saikosaponin A (SSa), a component of Radix Bupleuri, activates the DLL3 signaling pathway and promotes neurogenesis in the hippocampus, potentially improving depression-like behavior. In ovarian cancer, the expression of DLL3 was found to be associated with clinical factors such as stage and race, and it was also linked to immune cell infiltration. In small-cell lung carcinoma, DLL3 expression was associated with different molecular subtypes of the disease, and it was found to impact the tumor microenvironment and the efficacy of anti-PD-L1 antibody plus chemotherapy. Additionally, in a case report, a variant in the TPM2 gene was identified in a patient with spondylospinal thoracic dysostosis, a rare genetic disorder that affects the spine and ribs. These studies highlight the diverse applications of DLL3 in various diseases and biological processes.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human DLL3 Stable Cell Line (S01YF-1023-PY266). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Casey Smith (Verified Customer)

    What is the role of DLL3 in small cell lung cancer (SCLC) therapy? Aug 02 2023

    chat Patrick Liam (Creative Biolabs Scientific Support)

    DLL3 is a promising target in SCLC therapy. Rovalpituzumab tesirine, a directed agent against DLL3, has shown potential in treating SCLC by controlling cell differentiation, proliferation, and survival. Aug 02 2023

    chat Peyton Johnson (Verified Customer)

    Can DLL3 be targeted in neuroendocrine carcinomas? Aug 20 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    DLL3 is overexpressed in many neuroendocrine neoplasms (NENs) and is associated with poor clinical outcomes, especially in patients with neuroendocrine carcinoma (NEC), making it a clinically actionable target across NEN. Aug 20 2022
    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare